Why physicians start or stop prescribing a drug: Literature review and formulary implications (PDF)

Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.

Regeneron also announced an expanded contract with the U.S. government for the purchase of additional doses of REGEN-COV.

Point32Health is the name of the not-for-profit health care organization formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan.

The accreditation is effective through July 2024.

Some of the top medications were approved this summer, while others are awaiting FDA approval.

The pharma maker is partnering with the nonprofit Civica Rx to help reduce shortages in hospitals.